Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C, He Z, Guo M, Liu S, Wang Y, Qiu J, Li C, Wu D.
Anticancer Drugs. 2022 Mar 23. doi: 10.1097/CAD.0000000000001303. Epub ahead of print.
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.
Teyssonneau D, Thiery-Vuillemin A, Dariane C, Barret E, Beauval JB, Brureau L, Créhange G, Fiard G, Fromont G, Gauthé M, Ruffion A, Renard-Penna R, Mathieu R, Sargos P, Rouprêt M, Ploussard G, Roubaud G, On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'Urologie.
J Clin Med. 2022 Mar 21;11(6):1734. doi: 10.3390/jcm11061734.
"You Always Have It in the Back of Your Mind"-Feelings, Coping, and Support Needs of Women with Pathogenic Variants in Moderate-Risk Genes for Hereditary Breast Cancer Attending Genetic Counseling in Germany: A Qualitative Interview Study.